ERNA has not yet been described in immunotherapy-related cardiotoxicity patients but, for example, in breast cancer patients that are treated with the monoclonal antibody trastuzumab [148], which targets HER2/neu receptor [149]. This evidence concerns the gene ERBB2 and breast carcinoma.